Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Journal of Diabetes Investigation
|
April 9, 2025
Update on slowly progressive type 1 diabetes
Yoichi Oikawa, Akifumi Haisa, Atsushi Satomura, et al.
Diabetology International
|
January 29, 2025
Mitochondrial DNA 3243 mutation may be associated with positivity of zinc transporter 8 autoantibody in cases of slowly progressive type 1 diabetes mellitus
Erika Mitsui, Atsushi Satomura, Yoichi Oikawa, et al.
Journal of Diabetes Investigation
|
July 25, 2019
Bodyweight threshold for sudden onset of ketosis might exist in ketosis-prone type 2 diabetes patients
Atsushi Satomura, Yoichi Oikawa, Akifumi Haisa, et al.
The Journal of Clinical Endocrinology and Metabolism
|
December 18, 2021
Clinical Significance of Insulin Peptide-specific Interferon-γ-related Immune Responses in Ketosis-prone Type 2 Diabetes
Atsushi Satomura, Yoichi Oikawa, Akifumi Haisa, et al.
Clinical Immunology (Orlando, Fla.)
|
September 17, 2019
Significance of peripheral mononuclear cells producing interferon-γ in response to insulin B:9-23-related peptides in subtypes of type 1 diabetes
Yoichi Oikawa, Kumiko Sakamoto, Atsushi Satomura, et al.
Diabetes Research and Clinical Practice
|
July 31, 2024
High glutamic acid decarboxylase antibody titers may be associated with a decline in β-cell function over time and future insulin deficiency in latent autoimmune diabetes in adults
Akifumi Haisa, Yoichi Oikawa, Atsushi Satomura, et al.
BMC Endocrine Disorders
|
March 6, 2023
HLA typing of patients who developed subacute thyroiditis and Graves' disease after SARS-CoV-2 vaccination: a case report
Shigemitsu Yasuda, Seiya Suzuki, Shinnosuke Yanagisawa, et al.
Journal of Diabetes Investigation
|
May 22, 2024
Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of ipragliflozin in MASLD
Daisuke Ito, Satoshi Shimizu, Akifumi Haisa, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Journal of Diabetes Investigation
|
April 9, 2025
Update on slowly progressive type 1 diabetes
Yoichi Oikawa, Akifumi Haisa, Atsushi Satomura, et al.
Diabetology International
|
January 29, 2025
Mitochondrial DNA 3243 mutation may be associated with positivity of zinc transporter 8 autoantibody in cases of slowly progressive type 1 diabetes mellitus
Erika Mitsui, Atsushi Satomura, Yoichi Oikawa, et al.
Journal of Diabetes Investigation
|
July 25, 2019
Bodyweight threshold for sudden onset of ketosis might exist in ketosis-prone type 2 diabetes patients
Atsushi Satomura, Yoichi Oikawa, Akifumi Haisa, et al.
The Journal of Clinical Endocrinology and Metabolism
|
December 18, 2021
Clinical Significance of Insulin Peptide-specific Interferon-γ-related Immune Responses in Ketosis-prone Type 2 Diabetes
Atsushi Satomura, Yoichi Oikawa, Akifumi Haisa, et al.
Clinical Immunology (Orlando, Fla.)
|
September 17, 2019
Significance of peripheral mononuclear cells producing interferon-γ in response to insulin B:9-23-related peptides in subtypes of type 1 diabetes
Yoichi Oikawa, Kumiko Sakamoto, Atsushi Satomura, et al.
Diabetes Research and Clinical Practice
|
July 31, 2024
High glutamic acid decarboxylase antibody titers may be associated with a decline in β-cell function over time and future insulin deficiency in latent autoimmune diabetes in adults
Akifumi Haisa, Yoichi Oikawa, Atsushi Satomura, et al.
BMC Endocrine Disorders
|
March 6, 2023
HLA typing of patients who developed subacute thyroiditis and Graves' disease after SARS-CoV-2 vaccination: a case report
Shigemitsu Yasuda, Seiya Suzuki, Shinnosuke Yanagisawa, et al.
Journal of Diabetes Investigation
|
May 22, 2024
Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of ipragliflozin in MASLD
Daisuke Ito, Satoshi Shimizu, Akifumi Haisa, et al.
Page
of 1